The Australian Institute of Health and Welfare (AIHW) has developed a series of factsheets detailing various vaccine preventable diseases (VPD’s). These fact sheets provide information regarding the diseases, the number of cases reported in Australia, as well as rates of hospitalisation and deaths. The fact sheets can be found via the following link: AIHW fact sheets … Continued
In support of the environment and sustainability efforts, MVEC encourages online reporting of adverse events following immunisations on www.aefican.org.au; online reporting ensures accuracy of information submitted to SAEFVIC. However if a print copy is preferred, an updated SAEFVIC reporting form is now available on the SAEFVIC page.
The next Clinical Vaccinology Update (CVU) will be held on Friday 26th April, 2019 in the Copland Theatre (The Spot Building) at The University of Melbourne, Parkville. Topics covered will include updates on specific vaccines, adult and travel immunisations, as well as new immunisation resources. Watch this space when more information comes available on our … Continued
The World Health Organization (WHO) is currently hosting a series of webinars exploring specific topics in immunisation monitoring. These webinars are open to anyone with an interest in this area. Further information and details on registration can be found via the link below: Immunization Monitoring Academy: Webinars
The Australian Academy of Science has released a new video detailing the devastating impact of meningococcal disease. To access this video, as well as other meningococcal information, please follow the link below: MVEC: Meningococcal disease and vaccines
We have recently updated our hepatitis B reference page to incorporate the latest recommendations for serological testing, patients with impaired renal function as well as a new pathway for non-responders to the routine hepatitis B vaccine course. Please access the page below via the following link: MVEC: Hepatitis B
Menactra® should not be administered on the same day as Prevenar 13®. Studies have shown that co-administration may result in a decreased immune response to some of the pneumococcal serotypes. If both vaccines are required, Prevenar 13® should be administered first followed by Menactra® at least 4 weeks later. If these vaccines are inadvertently administered … Continued